Zika virus pathogenesis emerged as one of the most urgent research priorities in modern virology after ZIKV — a mosquito-borne Flavivirus first isolated in Uganda in 1947 — caused a major epidemic in the Americas in 2015–2016, revealing its previously unrecognized capacity to cross the placenta and cause congenital microcephaly, and to trigger Guillain-Barré syndrome (GBS) in adults. The outbreak prompted a WHO Public Health Emergency of International Concern and an explosion of mechanistic and translational research that has since transformed our understanding of how a single ssRNA virus can rewire developing neural circuits and evade innate immunity with striking precision.
Zika Virus Biology and Transmission
ZIKV belongs to the family Flaviviridae, genus Flavivirus — the same genus as dengue virus (DENV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus. Its genome is a ~10.7 kb positive-sense, single-stranded RNA molecule encoding a single open reading frame that is translated as a polyprotein and co- and post-translationally cleaved into three structural proteins — Capsid (C), pre-membrane/membrane (prM/M), and Envelope (E) — and seven non-structural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5.
Two primary lineages are recognized. The African lineage (original Zika Forest strains, both sylvatic and mosquito-adapted) has been associated with mild febrile illness. The Asian lineage, which spread across the Pacific and into the Americas, is linked to the 2015–2016 epidemic and the emergence of congenital Zika syndrome (CZS). A single amino acid change — S139N in the prM protein — was identified in the Asian epidemic strains and has been shown in experimental systems to enhance viral neurovirulence relative to ancestral African-lineage sequences, though the contribution of this and other mutations to the full epidemic phenotype continues to be studied.
Primary urban transmission occurs through the bite of Aedes aegypti mosquitoes; Ae. albopictus serves as a secondary, less-efficient vector in temperate regions. ZIKV is also transmitted sexually — with virus persisting in semen for weeks after acute infection — and vertically from mother to fetus via transplacental passage. First-trimester maternal infection carries the highest estimated risk of fetal anomalies, with estimates ranging from approximately 1–13% of first-trimester infections resulting in severe congenital outcomes, though risk is present throughout gestation.
Original isolation was documented by Dick, Kitchen, and Haddow in a rhesus monkey in the Zika Forest of Uganda in 1947, and reported in the Transactions of the Royal Society of Tropical Medicine and Hygiene (Dick et al., 1952). Phylogenetic analyses published by Faye and colleagues (PLoS Negl Trop Dis, 2014) clarified the two-lineage structure and the geographic origin of the epidemic strains.
Mechanisms of Zika Neuropathogenesis
The defining feature of ZIKV that distinguishes it from related flaviviruses is its tropism for neural progenitor cells (NPCs) — particularly the radial glia and outer radial glia (oRG) of the developing cortex — and its capacity to directly cause fetal microcephaly, a defect previously unattributed to any flavivirus. Several converging molecular mechanisms have been described.
NPC infection, apoptosis, and premature differentiation. ZIKV infects NPCs, radial glial cells, and cortical organoids derived from human iPSCs, causing apoptosis, mitotic arrest, and premature exit from the progenitor state, which collectively reduce the cortical neuron output. Li et al. demonstrated in human expanded cerebral organoids that ZIKV infection impairs cortical growth and folding — and that this effect is specific to human cells, since deletion of PTEN in mouse organoids does not phenocopy the same cortical expansion, underscoring the human-specificity of ZIKV neurotropism (Cell Stem Cell, 2016). A complementary review by Li, Saucedo-Cuevas, Shresta, and Gleeson in Neuron summarized prevailing models of neural stem cell entry, signaling hijacking, and the spectrum of adult and congenital neurological disease (Neuron, 2016).
NS5-mediated interferon antagonism. The ZIKV NS5 protein suppresses the host innate immune response by targeting the STING/TBK1/IRF3 pathway, thereby blocking type I interferon production. This is particularly consequential in the fetal brain, where intrinsic IFN-I signaling is limited, allowing viral spread with minimal innate immune counterpressure. This mechanism is distinct from the NS5 methyltransferase and RNA-dependent RNA polymerase activities of NS5, which are the primary antiviral drug targets.
Capsid protein disruption of centrosomal integrity. The ZIKV capsid protein interacts with centrosomal components and disrupts mitotic spindle assembly in NPCs, leading to mitotic errors, DNA damage, and apoptosis. The centrosomal pathway also intersects with ANKLE2 — a gene in which loss-of-function mutations independently cause autosomal recessive microcephaly — which has been implicated in ZIKV-mediated disruption of the LKB1-CDK5-MAPT signaling axis. This genetic convergence between viral pathogenesis and inherited microcephaly loci is a striking mechanistic insight.
Congenital Zika syndrome (CZS) encompasses microcephaly, cortical dysplasia with periventricular calcifications, eye malformations (chorioretinal lesions, macular scarring), and arthrogryposis — with the full spectrum dependent on timing and severity of fetal infection.
Guillain-Barré syndrome (GBS) in adults. The proposed mechanism for adult-onset GBS following ZIKV infection is molecular mimicry between ZIKV envelope protein or NS1 epitopes and gangliosides on peripheral nerve myelin, triggering autoimmune demyelination. This mechanistic attribution should be noted as proposed rather than definitively proven — the epidemiological association between ZIKV infection and GBS is strong, but the precise antigenic target of the cross-reactive immune response is still under investigation.
Preclinical Models for Zika Virus Research
Selecting the right Zika virus model is a critical decision in experimental design, because immunocompetent inbred mouse strains (C57BL/6, BALB/c) are largely resistant to systemic ZIKV infection — type I interferon signaling controls viral replication before overt disease develops. The field has addressed this through several complementary strategies.
Interferon receptor-deficient mouse models. The most widely used models exploit genetic or pharmacological ablation of the type I IFN pathway:
- AG129 mice: these mice carry knockouts of both the IFN-α/β receptor (on the A129 background) and the IFN-γ receptor, making them doubly deficient. They are highly permissive to ZIKV infection and develop neurological disease, weight loss, and mortality — making them the most stringent model for antiviral testing. Note: A129 mice carry only the IFN-α/β receptor knockout and are distinct from the double-KO AG129 strain.
- IFNAR1 KO (A129 and B6-Ifnar1−/−): single IFN-α/β receptor knockouts are permissive to ZIKV and useful for studying neuroinvasion and congenital transmission.
- Anti-IFNAR1 mAb-treated mice: transient pharmacological blockade of IFNAR1 in immunocompetent animals permits ZIKV infection without germline modification — a flexible model for studying adaptive immune responses in an otherwise intact immune background.
For studying vertical transmission, pregnant Ifnar1−/− dams mated with wild-type males generate heterozygous fetuses in an immunocompromised uterine environment — permitting maternal infection and fetal dissemination while maintaining a partially immunocompetent fetal genotype. Yellow fever vaccine (17DD)-based cross-protection has also been evaluated in A129 and immunocompetent BALB/c mice, illustrating the utility of these models for vaccine efficacy studies (Vicente Santos et al., PLoS Negl Trop Dis, 2021).
Non-human primates (NHP). Pigtail macaques (Macaca nemestrina) and rhesus macaques support natural ZIKV infection and vertical transmission, and have been used to confirm fetal brain pathology. NHP studies provided critical pre-licensure support for vaccine candidates in Phase I/II trials.
Human cortical organoids and iPSC-derived NPCs. Three-dimensional cortical organoids — derived from human embryonic stem cells or patient-specific iPSCs — are now the gold-standard system for studying ZIKV neurovirulence in a human genetic context. Infected organoids develop features of microcephaly: reduced organoid volume, progenitor zone collapse, and impaired folding. IPSC-derived NPCs are amenable to high-throughput small-molecule antiviral screening because they can be produced in quantity and are more physiologically relevant than Vero cell monolayers for CNS drug discovery. Browse BioHippo cell line research tools, including Vero E6 cells widely used for ZIKV propagation and plaque assays.
Diagnostic Methods and Research Assays
Accurate ZIKV detection and serology are central both to clinical management and to translational research. The diagnostics landscape is shaped by two persistent challenges: the short viremic window in serum (typically 3–5 days post-symptom onset) and extensive cross-reactivity within the flavivirus serogroup.
RT-qPCR is the gold standard for acute ZIKV infection. Urine has a higher viral load and detectable viral RNA for a longer duration than serum, making it the preferred matrix in the acute and sub-acute phase. Validated RT-qPCR assays target conserved regions of the ZIKV genome (typically NS5 or the E gene).
NS1 antigen detection. ZIKV NS1 is secreted into the bloodstream during active infection and can be detected by ELISA. However, ZIKV NS1 and DENV NS1 share structural epitopes, and commercially available NS1 ELISAs show significant cross-reactivity — NS1 antigen capture is best used as a screening tool in combination with RT-qPCR or confirmatory serology, not as a standalone diagnostic in dengue-endemic settings. BioHippo stocks Recombinant ZIKV NS1 Protein (C-His) for use in ELISA development, immunogen production, and serology assay construction.
Serology. Anti-ZIKV IgM and IgG ELISAs are used for surveillance and diagnosis beyond the viremic window. The major limitation is cross-reactivity with dengue antibodies — secondary dengue infection broadens the flavivirus antibody response and can produce ZIKV IgM reactivity in the absence of true ZIKV exposure. The plaque reduction neutralization test (PRNT) — measuring virus-specific neutralizing antibodies at ≥90% or ≥80% reduction endpoint — is the reference standard for confirmatory serology and is particularly important for distinguishing ZIKV from DENV in co-endemic regions. Research tools including anti-ZIKV NS1c monoclonal antibodies and anti-ZIKV Envelope nanobodies are available for assay development. For cross-reactive flavivirus serology studies, the anti-Dengue and Zika EDE1 antibody (EDE1C10) targets the Envelope Dimer Epitope 1, a conserved flavivirus epitope relevant to broadly neutralizing antibody research.
In BSL-2 research settings, pseudovirus neutralization assays (lentiviral or vesicular stomatitis virus vectors pseudotyped with the ZIKV envelope protein) offer a safer alternative to live ZIKV for measuring neutralizing antibody responses and screening antiviral compounds.
Vaccine and Antiviral Development
Despite intensive investment during and after the 2015–2016 epidemic, no ZIKV vaccine has received FDA approval as of July 2026. Multiple vaccine candidates have advanced through Phase I and Phase II clinical trials, spanning diverse platform technologies: mRNA vaccines (Moderna's mRNA-1893 and mRNA-1325), DNA vaccines (Inovio's GLS-5700; NIH VRC-ZKADNA090), purified inactivated vaccines (ZPIV from NIAID; VLA1601 from Valneva), live attenuated constructs (rZIKV/D4Δ30-713, chimeric platforms), and subunit/VLP approaches. Phase II trials for several candidates were completed, including Moderna's mRNA-1893 (808 participants; NCT04917861) and the NIH DNA vaccine VRC-705 (2,428 participants; NCT03110770) — but none has advanced to Phase III for regulatory approval, in part because the epidemic waned and endemic transmission dropped below the threshold needed to power an efficacy trial.
Antiviral targets under active investigation include the NS5 RNA-dependent RNA polymerase (RdRp) and methyltransferase domains, the NS2B-NS3 protease complex, and host entry factors. Nucleoside analogs with broad-spectrum flaviviral activity have shown in vitro inhibition of ZIKV replication. The NS2B-NS3 protease is a validated drug target shared with dengue — protease inhibitor scaffolds developed for dengue are being evaluated against ZIKV. BioHippo's catalog includes NS2B-NS3pro-IN-1, a small molecule inhibitor of the flavivirus NS2B-NS3 protease, for in vitro compound profiling studies.
Frequently Asked Questions
What is Zika virus?
Zika virus (ZIKV) is a positive-sense, single-stranded RNA virus in the genus Flavivirus (family Flaviviridae), related to dengue, West Nile, and Japanese encephalitis viruses. It was first isolated in 1947 from a rhesus monkey in the Zika Forest of Uganda. ZIKV is primarily transmitted by Aedes aegypti mosquitoes, but also spreads sexually and vertically from mother to fetus. Most ZIKV infections in adults are asymptomatic or cause a mild self-limiting febrile illness with rash, conjunctivitis, and arthralgia. Its global significance stems from the discovery that ZIKV infection during pregnancy can cause congenital microcephaly and a spectrum of fetal brain anomalies — findings that emerged clearly during the 2015–2016 epidemic in the Americas.
How does Zika virus cause microcephaly?
ZIKV causes microcephaly by infecting neural progenitor cells (NPCs) and radial glial cells in the developing fetal cortex, inducing apoptosis, premature neuronal differentiation, and mitotic arrest — all of which reduce the pool of proliferating cortical progenitors and thus the final neuron output. At the molecular level, ZIKV capsid protein disrupts centrosomal integrity and mitotic spindle assembly; NS5 suppresses the innate IFN-I response, allowing viral spread with limited immune control in the fetal brain; and autophagy is dysregulated in infected NPCs. The result is a thinner cortex, periventricular calcifications, and reduced head circumference — the defining features of congenital Zika syndrome (CZS). The risk is highest with first-trimester infection, when the cortical progenitor pool is most actively expanding.
What animal models are used in Zika virus research?
The most widely used Zika virus animal models are AG129 mice (double knockouts for IFN-α/β and IFN-γ receptors), IFNAR1 single-knockout mice (A129 or B6-Ifnar1−/−), and immunocompetent mice with transient anti-IFNAR1 antibody blockade. Each model has distinct properties: AG129 mice are the most permissive and are commonly used for antiviral efficacy testing; IFNAR1-KO mice are used for studying congenital transmission in pregnant dam models. Non-human primates (pigtail macaques, rhesus macaques) allow natural infection, vertical transmission, and fetal brain pathology assessment in a model phylogenetically closer to humans. Human cortical organoids and iPSC-derived neural progenitor cells are increasingly used because they capture human-specific aspects of ZIKV neurotropism and are suitable for high-throughput antiviral screening.
How is Zika virus diagnosed?
Zika virus diagnosis depends on the phase of infection. During the acute phase (first 7–14 days), RT-qPCR on serum or urine is the gold-standard test — urine viral loads are higher and detectable for longer than serum. ZIKV NS1 antigen ELISAs can detect antigen during the viremic window but have significant cross-reactivity with dengue NS1. After the viremic window, serological testing for anti-ZIKV IgM and IgG is used, but flavivirus antibody cross-reactivity (especially with dengue) limits specificity. The plaque reduction neutralization test (PRNT) is the reference standard for confirmatory serology and for distinguishing ZIKV from DENV in co-endemic settings. In research laboratories, pseudovirus neutralization assays offer a BSL-2 compatible alternative to live ZIKV for antibody measurements and drug screening.
Is there a Zika virus vaccine?
No Zika virus vaccine is approved by the FDA or any major regulatory agency as of mid-2026. Multiple vaccine platforms — including mRNA (Moderna mRNA-1893), DNA (NIH/Inovio), purified inactivated (ZPIV, VLA1601), and live attenuated constructs — have completed Phase I or Phase II clinical trials demonstrating safety and immunogenicity. However, none has advanced to Phase III licensure trials. The primary obstacle is that epidemic ZIKV transmission in the Americas subsided significantly after 2017, making it practically and ethically challenging to power a definitive field-efficacy trial. Research into ZIKV vaccines continues, with mRNA platforms considered among the most promising given their speed of development and immunogenicity in NHP models.
BioHippo Research Tools for Zika Virus Research
BioHippo offers a growing catalog of Zika virus research reagents spanning recombinant proteins, monoclonal and polyclonal antibodies, and small molecule tools:
- Recombinant ZIKV NS1 Protein (C-His) — mammalian-expressed, for ELISA development and serology assay construction
- Recombinant ZIKV Genome Polyprotein (partial) — for antigen-specific assays
- Anti-ZIKV NS1c Antibody (DV62.5) — recombinant monoclonal, validated for Western blot
- Anti-ZIKV Envelope Protein E Nanobody (SAA2297) — alpaca VHH, validated for ELISA, flow cytometry, and Western blot
- Anti-ZIKV Envelope E / DIII Domain Antibody (Z004) — human IgG1 monoclonal
- Anti-Dengue and Zika EDE1 Antibody (EDE1C10) — targets the Envelope Dimer Epitope 1 shared across flaviviruses; validated for ELISA, WB, and neutralization
- Rabbit Anti-ZIKA GP Polyclonal Antibody — IBT Bioservices, validated for ELISA and Western blot
- NS2B-NS3pro-IN-1 — small molecule inhibitor of the flavivirus NS2B-NS3 protease for in vitro antiviral screening
Browse the complete BioHippo antibodies catalog and recombinant proteins catalog for additional flavivirus and infectious disease research tools.
References
1. Dick GWA, Kitchen SF, Haddow AJ. Zika Virus (I). Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509–520.
2. Faye O et al. Molecular evolution of Zika virus during its emergence in the 20th century. PLoS Negl Trop Dis. 2014;8(1):e2486.
3. Li Y, Muffat J, Omer A, et al. Induction of Expansion and Folding in Human Cerebral Organoids. Cell Stem Cell. 2016;20(3):385–396.
4. Li H, Saucedo-Cuevas L, Shresta S, Gleeson JG. The Neurobiology of Zika Virus. Neuron. 2016;92(5):949–958.
5. Vicente Santos AC et al. Yellow fever vaccine protects mice against Zika virus infection. PLoS Negl Trop Dis. 2021;15(11):e0009907.